drugset

drugset / Trial / NCT00386087

Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy

NCT00386087 ↗

Phase 2 Completed 41 enrolled Eli Lilly and Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effectiveness of enzastaurin in the treatment of patients with metastatic breast cancer.

Timeline

Start: 2006-11
Primary completion: —
Completion: 2007-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	enzastaurin	Small molecule	—	Oral

Indications